Dupilumab can be used as an add-on biological therapy for the control of severe asthma: Dupilumab subcutaneous injection add-on therapy is an interleukin-4 receptor alpha antagonist, for patients aged six years and older with severe eosinophilic asthma, severe type two asthma, for adults or adolescents who require oral corticosteroid therapy.

The Egyptian Drug Authority (EDA) has approved Dupixent®️ (dupilumab) to be used with other asthma medicines as a maintenance therapy of severe asthma in adults, adolescents, and children aged six years and older who have difficulty controlling their asthma with their current medicines (eg corticosteroids).

Prof. Dr. Ahmed El Beleidy, Professor of Pediatrics Cairo University & President of ESUPMP said:

“Asthma is one of the most common chronic diseases in childhood.

Asthma is a chronic inflammatory disorder that affects the airways, resulting in recurrent episodes of wheezing, shortness of breath, chest tightness and coughing.

Although many patients achieve control with currently available therapies, an estimated 5-10 percent of patients remain symptomatic despite receiving large amounts of treatment.

Prof. Dr. Adel Riyad, Professor of Pediatrics Benha University & President of MICAP medical society said:

“The most common drawbacks experienced by patients with uncontrolled asthma are poor academic achievements due to increased school absence and unexpected emergency department visits as well as hospitalisations.

A high percentage of patients required home treatment, while many children required hospitalisation.

In Egypt, up to one in four asthmatic children are unable to attend school regularly because of poor asthma control.”

Prof. Dr. Ashraf Hatem, Professor of Pulmonology, Cairo University clarified that:

"Despite available treatments, severe asthma can severely impact children’s developing airways, causing sleepless nights, persistent coughing and wheezing, and potentially life-threatening exacerbations that require the use of systemic steroids that can negatively affect growth.”

“And through our practical experience, Dupixent®️ helped children aged six to 11 years breathe better, reduce the number of asthma attacks and improve their quality of life.”

Ahmed Hegazy, General Manager Sanofi Specialty Care Egypt & Sudan said:

“We at Sanofi, especially in the immunological diseases sector, work very hard and give priority to provide and meet patients’ needs with the best and latest treatments, which help improve our children's lives from asthma, and give hope to them and their families.”